Association of polymorphisms in MCP-1, CCR2, and CCR5 genes with the risk and clinicopathological characteristics of prostate cancer

DNA and Cell Biology

Volumn 31, Issue 8, 2012, Pages 1418-1424

  Kucukgergin, Canan ^a   Isman, Ferruh K ^b   Cakmakoglu, Bedia ^c   Sanli, Oner ^a   Seckin, Sule ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b Clinical Biochemistry Laboratory   (Turkey)

^c ISTANBUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; MONOCYTE CHEMOTACTIC PROTEIN 1;

ADULT; ARTICLE; CANCER RISK; CANCER STAGING; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER;

ALLELES; CHEMOKINE CCL2; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; RECEPTORS, CCR2; RECEPTORS, CCR5; RISK FACTORS;

EID: 84864625838     PISSN: 10445498     EISSN: 15577430     Source Type: Journal    
DOI: 10.1089/dna.2012.1716     Document Type: Article

References (42)

1. Abdi, R., Tran, T.B., Sahagun-Ruiz, A., Murphy, P.M., Brenner, B.M., Milford, E.L., McDermott, D.H. (2002). Chemokine receptor polymorphism and risk of acute rejection in human renal transplantation. J Am Soc Nephrol 13, 754-758.
2. Bektas-Kayhan, K., Unur, M., Boy-Metin, Z., and Cakmakoglu, B. (2012). MCP-1 and CCR2 gene variants in oral squamous cell carcinoma. Oral Dis 18, 55-59.
3. Chen, M.K., Yeh, K.T., Chiou, H.L., Lin, C.W., Chung, T.T., and Yang, S.F. (2011). CCR2-64I gene polymorphism increase susceptibility to oral cancer. Oral Oncol 47, 577-582.
4. Conti, I., and Rollins, B.J. (2004). CCL2 (monocyte chenoattractant protein-1) and cancer. Semin Cancer Biol 14, 149-154.
5. Craig, M.J., and Loberg, R.D. (2006). CCL2 (monocyte chemoattractant protein-1) in cancer bone metastases. Cancer Metastasis Rev 25, 611-619.
6. De Marzo, A.M., Platz, E.A., Sutcliffe, S., Xu, J., Grönberg, H., Drake, C.G., Nakai, Y., Isaacs, W.B., and Nelson, W.G. (2007). Inflammation in prostate carcinogenesis. (2007). Nat Rev Cancer 7, 256-269.
7. Degerli, N., Yilmaz, E., and Bardakci, F. (2005). The delta32 allele distribution of the CCR5 gene and its relationship with certain cancers in a Turkish population. Clin Biochem 38, 248-252.
8. Deshmane, S.L., Kremlev, S., Amini, S., and Sawaya, B.E. (2009). Monocyte chemoattractant protein-1 (MCP-1): An overview. J Interferon Cytokine Res 29, 313-326.
9. Ghilardi, G., Biondi, M.L, La Torre, A., Battaglioli, L., and Scorza R. (2005). Breast cancer progression and host polymorphisms in the chemokine system: Role of the macrophage chemoattractant protein-1 (MCP-1) - 2518 G allele. Clin Chem 51, 452-455.
10. Huang, Y., Paxton, W.A., Wolinsky, S.M., Neumann, A.U., Zhang, L., He, T., Kang, S., Ceradini, D., Jin, Z., Yazdanbakhsh, K., Kunstman, K., Erickson, D., Dragon, E., Landau, N.R., Phair, J., Ho, D.D., and Koup, R.A. (1996). The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 2, 1240-1243.
11. Ivansson, E.L., Gustavsson, I.M., Magnusson, J.J., Steiner, L.L., Magnusson, P.K., Erlich, H.A., and Gyllensten, U.B. (2007). Variants of chemokine receptor 2 and interleukin 4 receptor, but not interleukin 10 or Fas ligand, increase risk of cervical cancer. Int J Cancer 121, 2451-2457.
12. Kruszyna, L., Lianeri, M., Rubis, B., Knu1a, H., Rybczyńska, M., Grodecka-Gazdecka, S., and Jagodziński, P.P. (2011). CCL2- 2518 A/G single nucleotide polymorphism as a risk factor for breast cancer. Mol Biol Rep 38, 1263-1267.
13. Lavergne, E., Combadiere, C., Iga, M., Boissonnas, A., Bonduelle, O., Maho, M., Debre, P., and Combadiere, B. (2004). Intratumoral CC chemokine ligand5 overexpression delays tumor growth and increases tumor cell infiltration. J Immunol 173, 3755-3762.
14. Loberg, R.D., Day, L.L., Harwood, J., Ying, C., St. John, L.N., Giles, R., Neeley, C.K., and Pienta, K.J. (2006). CCL2 is a potent regulator of prostate cancer cell migration and proliferation. Neoplasia 8, 578-586.
15. Loberg, R.D., Ying, C., Craig, M., Yan, L., Snyder, L.A., and Pienta, K.J. (2007). CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. Neoplasia 9, 556-562.
16. Lu, Y., Cai, Z., Galson, D.L., Xiao, G., Liu, Y., George, D.E., Melhem, M.F., Yao, Z., and Zhang, J. (2006). Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion. Prostate 66, 1311-1318.
17. Lu, Y., Cai, Z., Xiao, G., Liu, Y., Keller, E.T., Yao, Z., and Zhang, J. (2007). CCR2 expression correlates with prostate cancer progression. J Cell Biochem 101, 676-685.
18. Lu, Y., Chen, Q., Corey, E., Xie, W., Fan, J., Mizokami, A., and Zhang, J. (2009). Activation of MCP-1/CCR2 axis promotes prostate cancer growth in bone. Clin Exp Metastasis 26, 161-169.
19. Mañes, S., Mira, E., Colomer, R., Montero, S., Real, L.M., Gómez- Moutón, C., Jiménez-Baranda, S., Garzón, A., Lacalle, R.A., Harshman, K., Ruíz, A., and Martínez, A.C. (2003). CCR5 expression influencesthe progression of human breast cancer in a p53-dependent manner. J Exp Med 198, 1381-1389.
20. Mizutani, K., Sud, S., McGregor, N.A., Martinovski, G., Rice, B.T., Craig, M.J., Varsos, Z.S., Roca, H., and Pienta, K.J. (2009). The chemokine CCL2 increases prostate tumor growth and bone metastasis through macrophage and osteoclast recruitment. Neoplasia 11, 1235-1242.
21. Mulé, J.J., Custer, M., Averbook, B., Yang, J.C., Weber, J.S., Goeddel, D.V., Rosenberg, S.A., and Schall, T.J. (1996). RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: Role of immune cell subpopulations. Hum Gene Ther 7, 1545-1553.
22. Nahon, P., Sutton, A., Rufat, P., Simon, C., Trinchet, J.C., Gattegno, L., Beaugrand, M., and Charnaux, N. (2008). Chemokine system polymorphisms, survival and hepatocellular carcinoma occurrence in patients with hepatitis C virusrelated cirrhosis. World J Gastroenterol 14, 713-719.
23. Nakayama, E.E., Tanaka, Y., Nagai, Y., Iwamoto, A., and Shioda, T. (2004). A CCR2-V64I polymorphism affects stability of CCR2A isoform. AIDS 18, 729-738.
24. Nelson, W.G., De Marzo, A.M., and Isaacs, W.B. (2003). Prostate cancer. N Engl J Med 349, 366-381.
25. O'Hayre, M., Salanga, C.L., Handel, T.M., and Allen, S.J. (2008). Chemokines and cancer: Migration, intracellular signalling and intercellular communication in the microenvironment. Biochem J 409, 635-649.
26. Petersen, D.C., Severi, G., Hoang, H.N., Padilla, E.J., Southey, M.C., English, D.R., Hopper, J.L., Giles, G.G., and Hayes, V.M. (2008). No association between common chemokine and chemokine receptor gene variants and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 17, 3615-3617.
27. Robinson, S.C., Scott, K.A., Wilson, J.L., Thompson, R.G., Proudfoot, A.E., and Balkwill, F.R. (2003). A chemokine receptor antagonist inhibits experimental breast tumor growth. Cancer Res 63, 8360-8365.
28. Rovin, B.H., Lu, L., and Saxena, R. (1999). A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. Biochem Biophys Res Commun 259, 344-348.
29. Sáenz-López, P., Carretero, R., Cózar, J.M., Romero, J.M., Canton, J., Vilchez, J.R., Tallada, M., Garrido, F., and Ruiz-Cabello, F. 2008 Genetic polymorphisms of RANTES, IL1-A, MCP-1 and TNF-A genes in patients with prostate cancer. BMC Cancer 8 382.
30. Sallusto, F., Lenig, D., Mackay, C.R., and Lanzavecchia, A. (1998). Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J Exp Med 187, 875-883.
31. Sanders, S.K., Crean, S.M., Boxer, P.A., Kellner, D., LaRosa, G.J., and Hunt, S.W. 3rd. (2000). Functional differences between monocyte chemotactic protein-1 receptor A and monocyte chemotactic protein-1 receptor B expressed in a Jurkat T cell. J Immunol 165, 4877-4883.
32. Sharma, S., Stolina, M., Zhu, L., Lin, Y., Batra, R., Huang, M., Strieter, R., and Dubinett, S.M. (2001). Secondary lymphoid organ chemokine reduces pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Cancer Res 61, 6406-6412.
33. Sica, A., Schioppa, T., Mantovani, A., and Allavena, P. (2006). Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: Potential targets of anti-cancer therapy. Eur J Cancer 42, 717-727.
34. Srivastava, A., Pandey, S.N., Choudhuri, G., and Mittal, B. (2008). CCR5 delta32 polymorphism: Associated with gallbladder cancer susceptibility. Scand J Immunol 67, 516-522.
35. Szalai, C., Duba, J., Prohászka, Z., Kalina, A., Szabó, T., Nagy, B., Horváth, L., and Császá r, A. (2001). Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD). Coincidence of elevated Lp(a) and MCP-1-2518 G/G genotype in CAD patients. Atherosclerosis 158, 233-239.
36. Tse, K.P., Tsang, N.M., Chen, K.D., Li, H.P., Liang, Y., Hsueh, C., Chang, K.P., Yu, J.S., Hao, S.P., Hsieh, L.L., and Chang, Y.S. (2007). MCP-1 promoter polymorphism at 2518 is associated with metastasis of nasopharyngeal carcinoma after treatment. Clin Cancer Res 13, 6320-6326.
37. Vaday, G.G., Peehl, D.M., Kadam, P.A., and Lawrence, D.M. (2006). Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate 66, 124-134.
38. Wada, Y., Nakashima, O., Kutami, R., Yamamoto, O., and Kojiro, M. (1998). Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration. Hepatology 27, 407-414.
39. Wong, L.M., Myers, S.J., Tsou, C.L., Gosling, J., Arai, H., and Charo, I.F. (1997). Organization and differential expression of the human monocyte chemoattractant protein 1 receptor gene. Evidence for the role of the carboxyl-terminal tail in receptor trafficking. J Biol Chem 272, 1038-1045.
40. Yeh, C.B., Tsai, H.T., Chen, Y.C., Kuo, W.H., Chen, T.Y., Hsieh, Y.H., Chou, M.C., and Yang, S.F. (2010). Genetic polymorphism of CCR2-64I increased the susceptibility of hepatocellular carcinoma. J Surg Oncol 102, 264-270.
41. Yoshie, O., Imai, T., and Nomiyama, H. (2001). Chemokines in immunity. Adv Immunol 78, 57-110.
42. Zafiropoulos, A., Crikas, N., Passam, A.M., and Spandidos, D.A. (2004). Significant involvement of CCR2-64I and CXCL12-3a in the development of sporadic breast cancer. J Med Genet 41, e59.